Latest Developments in Global Benign Prostatic Hyperplasia Drugs Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Benign Prostatic Hyperplasia Drugs Market

  • Pharmaceutical
  • Upcoming Report
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In April 2024, Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, “Takeda”), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, “SMBC”) today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily originating from Japan and toward the creation of innovative therapeutics
  • In February 2024, EMS released findings from a Phase III clinical trial evaluating the efficacy and safety of DTT106 for treating erectile dysfunction linked to benign prostatic hyperplasia. This trial was conducted across multiple centers, adhering to a randomized and double-blind design. The results highlighted DTT106's potential in addressing this dual condition effectively and safely
  • In February 2024, Resurge Therapeutics Inc. unveiled findings from a dose-escalation study assessing the safety and feasibility of RT-310 for treating lower urinary tract symptoms caused by benign prostatic hyperplasia. The study aimed to evaluate the therapeutic potential and tolerability of RT-310 in this condition. Results demonstrated promising outcomes, supporting further research and development efforts
  • In April 2022, Teleflex introduced the UroLift System in Japan to treat benign prostatic hyperplasia (BPH). This system had previously received FDA approval for addressing lower urinary tract symptoms caused by BPH. The launch marks a significant step in expanding the availability of this minimally invasive treatment option to a broader patient population in Japan
  • In October 2020, Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited announced a merger, expected to be finalized in 2023. The strategic partnership aims to create a global leader in developing and marketing innovative therapies for benign prostatic hyperplasia (BPH). This merger is set to enhance both companies' capabilities in addressing the growing demand for effective BPH treatments worldwide

Frequently Asked Questions

The market is segmented based on Segmentation, By Drug Type (Alpha-Blockers, 5-Alpha Reductase Inhibitors, Alpha-Adrenergic Blockers, Phosphodiesterase Type-5 Inhibitors, Beta-Blockers, and Others), Treatment Type (Medication, Surgery, and Other), Dosage (Tablet, Capsule, and Others), Route of Administration (Oral and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032 .
The Global Benign Prostatic Hyperplasia Drugs Market size was valued at USD 6.36 USD Billion in 2024.
The Global Benign Prostatic Hyperplasia Drugs Market is projected to grow at a CAGR of 6% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa , Brazil, Argentina and Rest of South America.